Advancing Alzheimer's diagnosis: Mayo Clinic's blood biomarker testing guide
The guide emphasizes the benefits of plasma-based biomarkers, such as increased accuracy, cost-effectiveness, and non-invasiveness, supporting better clinical trials and patient outcomes in dementia care.
According to the e-book, one in three seniors globally die with dementia and is costing the world about $2.8 trillion. This underscores the need for enhanced diagnosis and treatment. Mayo Clinic points to blood-based biomarkers for diagnosing mild cognitive impairment and dementia developed from Alzheimer’s. The laboratory says this form of testing is more accurate and leads to more efficient clinical trials.
Additionally, plasma-based biomarker testing brings quicker results and is cheaper to administer and not invasive. Mayo Clinic is offering a p-Tau217 plasma biomarker assay with 92% sensitivity and 96% specificity. The e-book lists additional Alzheimer’s test offerings from the laboratory. They work with the Mayo Clinic Behavioral Neurology to develop these tests and are offering collaboration with their scientists on clinical research.
